Genomma Lab Internacional | LABB

Stock Price
15.80
Daily Change
1.21 8.29%
Monthly
1.74%
Yearly
4.29%
Q2 Forecast
15.41
Peers Price Chg Day Year Date
AC Arca Continental 165.81 -5.81 -3.39% -2.76% Apr/25
ALFAA Alfa 12.80 0.66 5.44% 14.39% Apr/25
ALPEKA Alpek 12.65 -0.06 -0.47% -30.30% Apr/25
ASURB Grupo Aeroportuario del Sureste 596.70 17.03 2.94% 20.09% Apr/25
BIMBOA Grupo Bimbo 70.50 0.96 1.38% -23.28% Apr/25
CX Cemex 8.18 0.06 0.74% 41.28% Apr/25
GAPB Grupo Aeroportuario del Pacifico 310.01 9.67 3.22% -0.34% Apr/25
GCARSOA1 Grupo Carso 132.73 -2.61 -1.93% 33.41% Apr/25
GFNORTEO Banorte 175.09 0.36 0.21% 15.85% Apr/25
GRUMAB GRUMA 337.35 -2.87 -0.84% 25.41% Apr/25
HYPE3 Hypermarcas 27.15 -1.63 -5.66% -24.65% Apr/25
KIMBERA Kimberly-Clark de México 36.48 -0.30 -0.82% -9.86% Apr/25
LABB Genomma Lab Internacional 15.80 1.21 8.29% 4.29% Apr/25
ODPV3 Odontoprev 11.54 0.49 4.43% 16.80% Apr/25
RADL3 Raia Drogasil 24.95 0.17 0.69% -5.10% Apr/25

Indexes Price Day Year Date
MEXBOL IPC 57086 621.85 1.10% 5.67% Apr/25

Genomma Lab Internacional traded at 15.80 this Thursday April 25th, increasing 1.21 or 8.29 percent since the previous trading session. Looking back, over the last four weeks, Genomma Lab Internacional gained 1.74 percent. Over the last 12 months, its price rose by 4.29 percent. Looking ahead, we forecast Genomma Lab Internacional to be priced at 15.41 by the end of this quarter and at 14.35 in one year, according to Trading Economics global macro models projections and analysts expectations.

Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.